Development Strategy
Plan five production bases in the southeast, northwest, and central regions of the country, corresponding to the five market zones in the southeast, northwest, and central regions of the country.
Due to the fact that bioartificial liver requires live cold chain transportation and the Chinese Pharmacopoeia requires delivery within 24 hours. When used on patients, the production base is generally chosen as a high-speed rail transportation hub city.
The production base is located in the biopharmaceutical park, with a standard form of three floors, each with a height of 6 meters, and a single floor 2000-2500 square meters
Each standard factory covers an area of 10000-12000 square meters, with a total investment of 275 million yuan (factory construction and installation) The total repair cost is 0.662 million yuan, and the equipment cost is 208.8 million yuan. The designed production capacity is 50000 people, with an expected maximum production capacityValue 2.6 billion yuan, constructed in three phases

Organizational Structure

International Strategic Layout

Future Expectation


图片20.png图片21.png图片22.png


Business Development Model
We aim to provide cutting-edge liver health solutions and drive medical technology innovation And meet the growing health needs of patients, ultimately achieving the goal of improving global liver health.
Strategic Industrial Chain
  • Bioartificial liver (cell therapy) industry chain
  • Tonggan Enterprise Chain